
SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

Date of Report (Date of earliest event reported): November 7, 2006 (November 3, 2006)



CHEMBIO DIAGNOSTIC, INC.

(Exact name of registrant as specified in its charter)

Nevada
(State or other
jurisdiction
of Incorporation)

0-30379
(Commission File Number)

88-0425691
(IRS Employer

Identification Number)

3661 Horseblock Road
Medford, NY 11763
(Address of principal executive
offices)

631-924-1135
(Registrant's Telephone
Number)

N/A
(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

- ☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
 - ☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
 - ☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
 - ☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
-
-

ITEM 7.01. Regulation FD Disclosures.

On November 3, 2006 the Registrant issued the press release titled “Chembio Diagnostics to Present at the Paulson Investment’s Westergaard Small Cap Conference November 6 and the Rodman & Renshaw Healthcare Conference on November 8, 2006” included herein as Exhibit 99.1.

On November 6, 2006 the Registrant issued the press release titled “Chembio Receives Order for 990,000 SURE CHECK® HIV 1/2 Rapid Tests From Distributor in Mexico” included herein as Exhibit 99.2.

ITEM 9.01. Financial Statements and Exhibits

(d) Exhibits.

99.1 Press Release titled “[Chembio Diagnostics to Present at the Paulson Investment’s Westergaard Small Cap Conference November 6 and the Rodman & Renshaw Healthcare Conference on November 8, 2006](#)” issued November 3, 2006.

99.2 Press Release titled “[Chembio Receives Order for 990,000 SURE CHECK® HIV 1/2 Rapid Tests From Distributor in Mexico](#)” issued November 6, 2006.

In accordance with General Instruction B.2 of Form 8-K, the information in this Current Report on Form 8-K shall not be deemed “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934, nor shall it be deemed incorporated by reference in any filing. This Current Report on Form 8-K does not constitute a determination of whether any information included herein is material

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

Date: November 7, 2006

Chembio Diagnostics, Inc.

By: /s/ Lawrence A. Siebert
Lawrence A. Siebert
Chief Executive Officer



ChemBio Diagnostics to Present at the Paulson Investment's Westergaard Small Cap Conference November 6 and the Rodman & Renshaw Healthcare Conference on November 8, 2006

New York, November 3, 2006--- ChemBio Diagnostics, Inc.'s (OTCBB:CEMI) Lawrence Siebert, President and Chief Executive Officer, will be presenting at Paulson Investment's Westergaard Small Cap Conference on November 6, 2006 at the Waldorf Astoria Hotel in New York. Mr. Siebert will present in the morning session at 10:10 and 11:55 AM, and again in the afternoon session at 3:15 and 5:00 PM.

Mr. Siebert will also be presenting at the 2006 Rodman & Renshaw 8th Annual Healthcare Conference, November 8, 2006 at the Palace Hotel, in New York. The presentation is scheduled for 3:10 PM.

A live audio webcast of the presentation can be accessed on the dates of the presentations at www.chembio.com, and will be archived on the company's website for 30 days.

ABOUT CHEMBIO

ChemBio Diagnostics, Inc., a developer and manufacturer of rapid diagnostic tests for infectious diseases, is on the frontlines of the global battle against the AIDS pandemic. The Company has received marketing approval from the FDA for its SURE CHECK® HIV 1/2 and HIV 1/2 STAT-PAK™ rapid tests. The Company also manufactures rapid tests for veterinary Tuberculosis and Chagas Disease, and has developed a patent-pending technology, the Dual Path Platform (DPP™), for its next generation HIV and other rapid tests. For additional information please visit www.chembio.com.

FORWARD-LOOKING STATEMENTS

Statements contained herein that are not historical facts may be forward-looking statements within the meaning of the Securities Act of 1933, as amended. Forward-looking statements include statements regarding the intent, belief or current expectations of the Company and its management. Such statements are estimates only, as the Company has not completed the preparation of its financial statements for those periods, nor has its auditor completed the audit of those results. Actual revenue may differ materially from those anticipated in this press release. Such statements reflect management's current views, are based on certain assumptions and involve risks and uncertainties. Actual results, events, or performance may differ materially from the above forward-looking statements due to a number of important factors, and will be dependent upon a variety of factors, including, but not limited to ChemBio's ability to obtain additional financing, to obtain regulatory approvals in a timely manner, and the demand for ChemBio's products. ChemBio undertakes no obligation to publicly update these forward-looking statements to reflect events or circumstances that occur after the date hereof or to reflect any change in ChemBio's expectations with regard to these forward-looking statements or the occurrence of unanticipated events. Factors that may impact ChemBio's success are more fully disclosed in ChemBio's most recent public filings with the U.S. Securities and Exchange Commission.

Contact:

The Investor Relations Group 212-825-3210

Investors: James Carbonara

Media: Susan Morgenbesser



ChemBio Receives Order for 990,000 SURE CHECK® HIV 1/2 Rapid Tests From Distributor in Mexico

Will be Used in Mexican Federal Program to Screen Pregnant Women for HIV

Medford, N.Y. - November 6, 2006 - ChemBio Diagnostics, Inc. (OTCBB:CEMI) has received a purchase order for 990,000 of its SURE CHECK® HIV 1/2 rapid tests from the Company's exclusive distributor in Mexico. The tests will be used for the Mexican Ministry of Health program to screen pregnant women. During the next several weeks, a shipment schedule will be finalized with the distributor.

Avi Pelossof, Vice President of Sales Marketing and Business Development of ChemBio, commented, "We are pleased that SURE CHECK® HIV 1/2 was selected by the Mexican Ministry of Health for what we believe to be the largest scale implementation of rapid HIV tests in that country. This order also underscores the progress we are making in the Latin American market with our products: During the last year we have grown our business in that region through our agreement with Bio-Manguinhos (an affiliate of the Brazilian Ministry of Health), the national Chagas screening program in Bolivia (using our Chagas STAT-PAK™), and now this important program in Mexico. We believe this international business can provide us with continued growth as we enter the U.S. HIV rapid test market through the agreement we recently announced with our strategic partner, Inverness Medical Innovations, Inc. (AMEX: IMA)."

The Mexican Ministry of Health program is designed to screen pregnant women throughout Mexico in an attempt to prevent transmission of the HIV virus to children. As part of the program, women who test positive for HIV can receive counseling, and they and their newborns can also be put on treatment and receive antiretroviral drugs.

ABOUT CHEMBIO

ChemBio Diagnostics, Inc., a developer and manufacturer of rapid diagnostic tests for infectious diseases, is on the frontlines of the global battle against the AIDS pandemic. The Company has received marketing approval from the FDA for its SURE CHECK® HIV 1/2 and HIV 1/2 STAT-PAK™ rapid tests. The Company also manufactures rapid tests for veterinary Tuberculosis and Chagas Disease, and has developed a patent-pending technology, the Dual Path Platform (DPP™), for its next generation HIV and other rapid tests. For additional information please visit www.chembio.com.

FORWARD-LOOKING STATEMENTS

Statements contained herein that are not historical facts may be forward-looking statements within the meaning of the Securities Act of 1933, as amended. Forward-looking statements include statements regarding the intent, belief or current expectations of the Company and its management. Such statements are estimates only, as the Company has not completed the preparation of its financial statements for those periods, nor has its auditor completed the audit of those results. Actual revenue may differ materially from those anticipated in this press release. Such statements reflect management's current views, are based on certain assumptions and involve risks and uncertainties. Actual results, events, or performance may differ materially from the above forward-looking statements due to a number of important factors, and will be dependent upon a variety of factors, including, but not limited to ChemBio's ability to obtain additional financing, to obtain regulatory approvals in a timely manner, and the demand for ChemBio's products. ChemBio undertakes no obligation to publicly update these forward-looking statements to reflect events or circumstances that occur after the date hereof or to reflect any change in ChemBio's expectations with regard to these forward-looking statements or the occurrence of unanticipated events. Factors that may impact ChemBio's success are more fully disclosed in ChemBio's most recent public filings with the U.S. Securities and Exchange Commission.

Contact:

The Investor Relations Group 212-825-3210

Investors: James Carbonara

Media: Susan Morgenbesser